|
Laboratory variables
| | | |
|
Functional MBL serum level, μg/mla
|
1.60 (0.04–7.00)
|
1.40 (0.04–7.60)
|
0.316
|
|
Functional MBL serum level <0.05 μg/ml
|
2/23 (9%)
|
11/80 (14%)
|
0.522
|
|
MBL-induced C4 deposition on mannan, percentagea
|
64.8 (3.4–400)
|
71.1 (1.1–400)
|
0.550
|
|
MBL-induced C4 deposition on mannan <10%
|
5/23 (22%)
|
16/80 (20%)
|
0.856
|
|
MBL pathway activity, percentagea
|
14.1 (0.1–111)
|
17.3 (0.1–119)
|
0.806
|
|
MBL pathway activity <10%
|
10/23 (44%)
|
34/80 (43%)
|
0.934
|
|
Clinical variables
| | | |
|
Disease duration at follow-up, years
|
12.5 ± 7.4
|
5.1 ± 5.7
|
0.0001
|
|
Previous SLE glomerulonephritis
|
10/23 (44%)
|
10/80 (10%)
|
0.001
|
|
Treatment variables
|
Use <3 months before the first major infection
|
Previous use ever since lupus diagnosis
| |
|
Oral corticosteroids
|
17/23 (74%)
|
41/80 (51%)
|
0.916
|
|
Intravenous methylprednisolone
|
5/23 (22%)
|
9/80 (11%)
|
0.204
|
|
Hydroxychloroquine
|
6/23 (26%)
|
70/80 (88%)
|
0.0001
|
|
Methotrexate
|
0/23 (0%)
|
9/80 (11%)
|
0.094
|
|
Azathioprine
|
8/23 (35%)
|
21/80 (26%)
|
0.424
|
|
Oral cyclophosphamide
|
1/23 (4%)
|
1/80 (1%)
|
0.373
|
|
Intravenous cyclophosphamide
|
4/23 (17%)
|
4/80 (5%)
|
0.065
|
